Drug Trial Radar · NCT06430801
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Jun 5, 2024
Primary completion
Oct 30, 2028
Study completion Nov 12, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA). Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).
Conditions
- Crohn's Disease
Interventions
IV TulisokibartDrug
Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
SC TulisokibartDrug
Humanized monoclonal antibody that binds human TL1A, administered subcutaneously
IV PlaceboOther
Placebo matching IV tulisokibart
SC PlaceboOther
Placebo matching SC tulisokibart
Primary outcomes
What the sponsor says the trial is designed to measure.
- Study 1 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per Crohn's Disease Activity Index (CDAI) Score at Week 52Time frame: Week 52
- Study 1 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 52Time frame: Week 52
- Study 1: Percentage of Participants Achieving Endoscopic Response at Week 52Time frame: Week 52
- Study 1 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 12Time frame: Week 12
- Study 1 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 12Time frame: Week 12
- Study 1: Percentage of Participants Achieving Endoscopic Response at Week 12Time frame: Week 12
- Study 2 [US/FDA Only]: Percentage of Participants Achieving Clinical Remission per CDAI Score at Week 12Time frame: Week 12
- Study 2 [EU/EMA Only]: Percentage of Participants Achieving Clinical Remission per Stool Frequency and Abdominal Pain Score at Week 12Time frame: Week 12
- Study 2: Percentage of Participants Achieving Endoscopic Response at Week 12Time frame: Week 12
Locations
499 sites in 47 countries. Site status is shown where the registry gives one.
Digestive Health Specialists ( Site 5064)
Dothan, Alabama · Completed
Arizona Arthritis & Rheumatology Research, PC ( Site 5094)
Phoenix, Arizona · Completed
GI Alliance - Sun City ( Site 5118)
Sun City, Arizona · Recruiting
University of Arizona Clinical and Translational Sciences Research Center ( Site 5111)
Tucson, Arizona · Recruiting
University of Arkansas for Medical Sciences ( Site 5147)
Little Rock, Arkansas · Recruiting
Clinnova Research ( Site 5110)
Anaheim, California · Recruiting
Southern California Research Center ( Site 5044)
Coronado, California · Recruiting
Om Research LLC ( Site 5038)
Lancaster, California · Recruiting
Cedars Sinai Medical Center ( Site 5080)
Los Angeles, California · Recruiting
UCLA Clinical & Translational Research Center (CTRC) ( Site 5116)
Los Angeles, California · Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 5128)
Orange, California · Recruiting
Om Research LLC ( Site 5045)
Oxnard, California · Recruiting
Clinical Applications Laboratories ( Site 5123)
San Diego, California · Recruiting
Amicis Research Center ( Site 5055)
Valencia, California · Completed
University of Colorado Anschutz Medical Campus-Division of Gastroenterology and Hepatology ( Site 5026)
Aurora, Colorado · Recruiting
Peak Gastroenterology Associates ( Site 5023)
Colorado Springs, Colorado · Recruiting
South Denver Gastroenterology, PC ( Site 5132)
Englewood, Colorado · Recruiting
Rocky Mountain Gastroenterology ( Site 5082)
Lakewood, Colorado · Recruiting
Medical Research Center of Connecticut ( Site 5005)
Hamden, Connecticut · Completed
Yale University School of Medicine-Digestive Disease ( Site 5019)
New Haven, Connecticut · Recruiting
Emerson Clinical Research Institute ( Site 5051)
Washington D.C., District of Columbia · Recruiting
Gastroenterology Consultants of Clearwater ( Site 5052)
Clearwater, Florida · Active not recruiting
Covenant Metabolic Specialists, LLC ( Site 5150)
Fort Myers, Florida · Recruiting
Nature Coast Clinical Research - Inverness ( Site 5042)
Inverness, Florida · Recruiting
Atlantic Medical Research ( Site 5073)
Margate, Florida · Active not recruiting
Sanchez Clinical Research ( Site 5144)
Miami, Florida · Recruiting
AdventHealth Orlando ( Site 5131)
Orlando, Florida · Recruiting
Endoscopic Research Inc ( Site 5061)
Orlando, Florida · Recruiting
Orlando Health-Digestive Health Institute ( Site 5010)
Orlando, Florida · Completed
USF Health Carol and Frank Morsani Center for Advanced Healthcare ( Site 5039)
Tampa, Florida · Recruiting
Covenant Metabolic Specialists, LLC ( Site 5143)
University Park, Florida · Recruiting
Morehouse School Of Medicine ( Site 5071)
Atlanta, Georgia · Recruiting
Atlanta Center for Gastroenterology ( Site 5035)
Decatur, Georgia · Completed
Gastroenterology Associates of Central Georgia ( Site 5048)
Macon, Georgia · Recruiting
Eagle Clinical Research ( Site 5089)
Chicago, Illinois · Completed
University of Chicago Medical Center ( Site 5066)
Chicago, Illinois · Recruiting
Endeavor Health ( Site 5018)
Evanston, Illinois · Recruiting
GI ALLIANCE - GURNEE ( Site 5003)
Gurnee, Illinois · Recruiting
Indiana University Health University Hospital ( Site 5022)
Indianapolis, Indiana · Recruiting
Iowa Digestive Disease Center ( Site 5007)
Clive, Iowa · Recruiting
Showing 40 of 499 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.